about
Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.Best practice in the use of natalizumab in multiple sclerosis.The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data.Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring.Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.Natalizumab in the pediatric MS population: results of the Italian registryTreating multiple sclerosis with natalizumab.The link between VLA-4 and JC virus reactivation.The management of pediatric multiple sclerosis.Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.Can new chemical therapies improve the management of multiple sclerosis in children?Affective disorders and Health-Related Quality of Life (HRQoL) in adolescents and young adults with Multiple Sclerosis (MS): the moderating role of resilience.Cognitive deficits in pediatric-onset multiple sclerosis: what does the future hold?JC virus antibody status in a pediatric multiple sclerosis cohort: prevalence, conversion rate and influence on disease severity.Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.Current therapeutic options in pediatric multiple sclerosis.Therapy of highly active pediatric multiple sclerosis.Treatment of pediatric multiple sclerosis.Pediatric multiple sclerosis: a review.
P2860
Q30354658-81D8D84C-42B2-41FE-BA9A-8E97FDB8C423Q30597618-D87D5122-3E7D-40CC-9458-E9857605A3A7Q30986945-7DC3FD49-C844-4289-A9DA-7FEC6EA0DF53Q35093103-9E51F483-CD6B-43FA-A9B3-A2D65AD0444BQ35228937-B3358E32-F3A5-4ECC-8AF8-242EC5524E52Q35788938-2DBE6BC6-3AB4-46F6-861D-1808C9AA66FEQ37957123-3BC203DD-E002-4633-8AB5-AC35F958DD51Q37965603-D99CC7B8-F383-41DC-817E-E6A9BDCDDBB5Q38036853-C0CE3085-D7C4-4A85-87E1-CF9654AD673EQ38167347-BE928221-0F00-43E1-96A5-7BA160FE24E9Q39024427-A23FB74D-FBD9-46CD-9CCC-77FA8B7F1A1CQ39121124-E1E58F16-0B3E-496C-8165-30B391961634Q39191862-D8DA938D-6BBE-47C0-8620-FA098492B0CCQ42203290-A47CF09C-E8F9-4A9D-AF95-663DD23141CBQ48167039-96129685-5F34-40A6-988C-558D518B2AFBQ48805758-FAC5D6F5-A0DA-420C-B950-301065EE165AQ49968003-4828B669-1B47-4B15-BB9D-B70344875BD2Q53609248-DCA5510A-38B7-43EA-9FBD-9BE936BB8D61Q53838633-D5FE3ECC-0884-4EC1-A02E-6C0EF013F9D2
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Natalizumab in pediatric multiple sclerosis patients.
@ast
Natalizumab in pediatric multiple sclerosis patients.
@en
Natalizumab in pediatric multiple sclerosis patients.
@nl
type
label
Natalizumab in pediatric multiple sclerosis patients.
@ast
Natalizumab in pediatric multiple sclerosis patients.
@en
Natalizumab in pediatric multiple sclerosis patients.
@nl
prefLabel
Natalizumab in pediatric multiple sclerosis patients.
@ast
Natalizumab in pediatric multiple sclerosis patients.
@en
Natalizumab in pediatric multiple sclerosis patients.
@nl
P2860
P356
P1476
Natalizumab in pediatric multiple sclerosis patients.
@en
P2093
P2860
P304
P356
10.1177/1756285610381526
P577
2010-09-01T00:00:00Z